Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO

Kidney
4 Mins Read0

Breast Cancer Genetic Testing – Should Doctors Use ctDNA? Nathalie McDowell Johnson, MD 

Breast
3 Mins Read21

90% Don’t Know Of Simple Genetic Test for Cancer – Kevin Hughes, MD

Breast
3 Mins Read17

FDA Accelerates Approval of Afamitresgene Autoleucel for Advanced Synovial Sarcoma

Sarcoma
2 Mins Read8

KRYSTAL-1: Adagrasib + Cetuximab Promise for KRASG12C Colorectal Cancer – Scott Kopetz, MD [AACR 2024]

Revolutionizing Pancreatic Cancer Detection: The Groundbreaking Role of Liquid Biopsies – Ajay Goel, PhD [AACR 2024]

Linvoseltamab: A Groundbreaking Advance in Multiple Myeloma Treatment

Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer

Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators

Inspiring Innovations: The Impact of the MOASC Young Investigator Award

What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD

What Are the Latest Melanoma Treatment Advances? [87 Slides] Justin Moyers, MD

2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides]

Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides]

2024 Optimistic Advances in Colorectal Cancer: New Genetic Discoveries & Dancing

Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES]

Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES]

Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]

BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023]

Managing High-Risk Hematologic Malignancies in the Community [ASH 2023]

Brexucabtagene Autoleucel ZUMA-2 and ZUMA-18, Expanded Access Study [ASH 2023]

Daratumumab and the VDPACE Outcomes in Multiple Myeloma [ASH 2023]

BTK Degrader BGB-16673:Phase 1 Results in B-Cell Malignancies [ASH 2023]

Elranatamab for Black Patients with Relapsed Multiple Myeloma [ASH 2023]

Mosunetuzumab 1st Line Follicular Lymphoma Phase 2 [ASH 2023]

Lymphoma
1 Min Read31

Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…

Mechanical Conditioning score is higher in circulating tumor cells

Breast
1 Min Read74

By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in…

Teclistamab Outpatient Admin in Multiple Myeloma

Multiple Myeloma
2 Mins Read45

By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI…

Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023]

Other
1 Min Read52

In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…

Fertility Preservation and assisted reproductive technologies (ART) – SABCS 2023

Breast
3 Mins Read30

By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive…

Efgartigimod in Thrombocytopenia Phase 3 ADVANCE IV Trial Results [ASH 2023]

Other
2 Mins Read54

At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…

Development & Evaluation E-HIPI HoLISTIC Consortium Report [ASH 2023]

Hodgkin Lymphoma
2 Mins Read74

In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a…

BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023]

Chronic Lymphocytic Leukemia
2 Mins Read174

David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member…

Liso-Cel and ctDNA in LBCL Phase 3 TRANSFORM Study

Lymphoma
2 Mins Read57

By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…

Remodeling microenvironment promotes a tumor-permissive locale for ER+ breast cancer – SABCS 2023

Breast
2 Mins Read42

By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved…

Marlise Luskin,MD, MSCE [slides]-Venetoclax and BCL2 Inhibitors

Elias Jabbour, MD [slides]-Exploring Blina, CAR T-Cell Strategies

Charles Mullighan,MD[slides]-Genomic Classification-Corrected

Session 1 Panel Discussion-AML: Groups, Molecular Markers and MRD

Ryan Fitzpatrick, CEO, MD Education- AML-ALL Focus 2023- Opening

Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]

Multiple Myeloma
13 Mins Read159

Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…

What is the greatest value of ctDNA testing in breast cancer?

January 10, 2024

Where do you see the greatest utility of ctDNA testing in patients with solid tumors?

January 10, 2024

IFN-alpha and plasmacytoid dendritic cells in TNBC FinXX Trial

December 12, 2023

Practice patterns for sequential use of antibody-drug conjugate after antibody-drug

December 12, 2023

Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators

General
3 Mins Read182

… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…

Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES]

March 13, 2024

Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES]

March 13, 2024

2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides]

March 16, 2024